alphameprodine

Alphameprodine is a synthetic opioid analgesic and a structural analogue of meperidine (pethidine). It acts primarily as an agonist at the mu-opioid receptor, producing typical opioid effects such as analgesia, euphoria, sedation, itching, nausea, and respiratory depression. Alphameprodine was first marketed by Hoffmann-LaRoche in 1949 for use as an injectable narcotic analgesic in labor and delivery and urologic procedures. It has a rapid onset of action (analgesia within 1–2 minutes IV; within 10 minutes SC) with a short duration (30–90 minutes IV; up to two hours SC), and is metabolized in the liver with excretion mainly via urine. Due to its high potential for abuse and lack of accepted medical use in the United States, it is classified as a Schedule I controlled substance by the DEA[1][2][3][4][5].

Other names

alfameprodinaalphameprodinum468-51-9